Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

Effects of B cell depletion by rituximab, a monoclonal antibody to CD20, were studied in patients with relapsing MS that had not responded optimally to standard immunomodulatory therapies. Flow cytometry demonstrated reduced cerebrospinal fluid (CSF) B cells and T cells in most patients at 6 months...

Full description

Saved in:
Bibliographic Details
Published inJournal of neuroimmunology Vol. 180; no. 1; pp. 63 - 70
Main Authors Cross, Anne H., Stark, Jennifer L., Lauber, Joanne, Ramsbottom, Michael J., Lyons, Jeri-Anne
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.11.2006
Subjects
Online AccessGet full text

Cover

Loading…